Dry Powder Inhaler Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Dry Powder Inhaler Devices Pipeline Market Report Overview
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. The dry powder inhaler devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.
| Key Territory | · The US
· Europe · Australia · China · Canada |
| Key Regulatory Paths | · 510(k)
· CE · MDL · NMPA · TGA |
| Leading Companies | · 1nhaler Ltd
· Acorda Therapeutics Inc · Advent Pharmaceuticals Pty Ltd · Aespira Ltd. · AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive) |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Dry Powder Inhaler Devices Pipeline Market Segmentation by Territories
A few of the key territories with the dry powder inhaler devices pipeline market are the United States, Europe, Australia, China, and Canada among others. As of May 2024, the US accounts for the highest number of dry powder inhaler devices pipeline products.
Dry Powder Inhaler Devices Pipeline Market Analysis by Territories, 2024 (%)
Buy the Full Report for More Territory Insights into the Dry Powder Inhaler Devices Pipeline Market
Dry Powder Inhaler Devices Pipeline Market Segmentation by Regulatory Paths
A few of the key regulatory paths in the dry powder inhaler devices pipeline products market are 510(k), CE, MDL, NMPA, and TGA among others. As of May 2024, 510(k) accounts for the most followed pathway for pipeline products in the dry powder inhaler devices market.
Dry Powder Inhaler Devices Pipeline Market Analysis by Regulatory Paths, 2024 (%)
Buy the Full Report for More Regulatory Path Insights into the Dry Powder Inhaler Devices Pipeline Market
Dry Powder Inhaler Devices Pipeline Market – Competitive Landscape
A few of the key companies associated with the dry powder inhaler devices pipeline market are 1nhaler Ltd, Acorda Therapeutics Inc., Advent Pharmaceuticals Pty Ltd, Aespira Ltd., and AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive)among others.
1nhaler Ltd: 1nhaler Ltd is a medical device company engaged in the manufacturing, distribution, and marketing of dry powder inhaler. The company is headquartered in Edinburgh, Scotland, the UK.
Acorda Therapeutics Inc: Acorda Therapeutics Inc (Acorda), is a biopharmaceutical company that discovers, develops, and markets therapies for treating patients with neurological disorders. The company’s portfolio encompasses marketed products for the treatment of multiple sclerosis (MS) and for the intermittent treatment of people with Parkinson’s taking levodopa or carbidopa who experience off episodes. The company sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.
Dry Powder Inhaler Devices Pipeline Market Analysis by Companies, 2024
Buy the Full Report for More Company Insights into the Dry Powder Inhaler Devices Pipeline Market
Segments Covered in the Report
Dry Powder Inhaler Devices Pipeline Market Territories Outlook (2024)
- The US
- Europe
- Australia
- China
- Canada
Dry Powder Inhaler Devices Pipeline Market Regulatory Paths Outlook (2024)
- 510(k)
- CE
- MDL
- NMPA
- TGA
Scope
This report provides:
- Extensive coverage of the dry powder inhaler devices under development.
- An exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
- Reviews of major players involved in the development of dry powder inhaler devices and lists all their pipeline projects.
- Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
- Key clinical trial data of ongoing clinical trials specific to pipeline products.
- Recent developments in the segment/industry.
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies.
- Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
- Identify and understand important and diverse types of dry powder inhaler devices under development.
- Develop market-entry and market-expansion strategies.
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
- Carry out an in-depth analysis of the product’s current stage of development, territory, and estimated launch date.
Acorda Therapeutics Inc
Advent Pharmaceuticals Pty Ltd
Aespira Ltd.
AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive)
Bayer AG
Belhaven Biopharma Inc
Cambridge Healthcare Innovations Ltd
Creare LLC
DMK Pharmaceuticals Corp
Glenmark Pharmaceuticals Ltd
GSK plc
Hovione Technology Ltd
Iconovo AB
Lupin Pharmaceuticals Inc
MannKind Corp
Monash University
Nektar Therapeutics
Ology Bioservices Inc
OPKO Health Inc
OtiTopic Inc
Phargentis SA
PureIMS BV
Quench Medical Inc
Receptor Life Sciences Inc
Respira Therapeutics Inc
Respirent Pharmaceuticals Co Ltd
Sandoz International GmbH
Sheffield Hallam University
Shin Nippon Biomedical Laboratories Ltd
Spyryx Biosciences Inc (Inactive)
Syntara Ltd
Teva Pharmaceutical Industries Ltd
Transpire Bio Inc
United Therapeutics Corp
University of Kansas
University of Sydney
University of Texas Medical Branch at Galveston
Vectura Group Plc
Verona Pharma Plc
Virginia Commonwealth University
Table of Contents
Table
Figures
Frequently asked questions
-
Which territory has the highest number of products in the dry powder inhaler devices pipeline market as of May 2024?
As of May 2024, the US accounts for the highest number of pipeline products in the dry powder inhaler devices market.
-
Which is the most followed regulatory pathway in the dry powder inhaler devices pipeline market as of May 2024?
As of May 2024, 510(k) accounts for the most followed pathway for pipeline products in the dry powder inhaler devices market.
-
Which are the major companies operating in the dry powder inhaler devices pipeline market?
A few of the key companies associated with the dry powder inhaler devices pipeline market are 1nhaler Ltd, Acorda Therapeutics Inc., Advent Pharmaceuticals Pty Ltd, Aespira Ltd., and AKELA Pharma Inc. (Formerly LAB International, Inc.) (Inactive)among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Dry Powder Inhaler Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
